This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
Conditions: Advanced Breast Cancer; Female Breast Cancer Interventions: Drug: FCN-437c, Letrozole or anastrozole, Goserelin acetate; Drug: Placebo, Letrozole or anastrozole, Goserelin acetate Sponsor: Ahon Pharmaceutical Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 30, 2022 Category: Research Source Type: clinical trials
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Condition: Breast Cancer Interventions: Drug: LOXO-783; Drug: Fulvestrant; Drug: Imlunestrant; Drug: Abemaciclib; Drug: Anastrozole, Exemestane, or Letrozole; Drug: Paclitaxel Sponsors: Eli Lilly and Company; Loxo Oncology, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2022 Category: Research Source Type: clinical trials
